News
Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck’s cancer medicine ...
Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an estimated price of $47 per share – potentially valuing the ...
5d
News-Medical.Net on MSNTailored treatment guided by dual biopsy approach may improve outcomes for patients with advanced cancersPatients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...
Merck & Company (MRK – Research Report) received a Hold rating and an $85.00 price target from Cantor Fitzgerald analyst Carter Gould yesterday. The company’s shares closed yesterday at $77.85 ...
Drugmaker's stock gains as quarterly profit and sales extend a long string of beats and full-year outlook is kept intact Shares of Merck & Co. were headed higher in early Thursday trading ...
Merck KGaA is building up its portfolio and pipeline with a $3.9 billion deal to acquire SpringWorks Therapeutics, a company with two FDA-approved rare tumor drugs, both of which offer the ...
NEW YORK/FRANKFURT (Reuters) - Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of ...
Marchetti has had a consultant/advisory role for Bristol Myers Squibb, Roche/Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. He is also a member of the advisory board of ...
(RTTNews) - Responding to press reports, Merck KGaA (MKGAY.PK) confirmed late-stage discussions with SpringWorks Therapeutics Inc. (SWTX) on a potential acquisition. Merck KGaA noted that the ...
Global language service provider thebigword is proud to announce it has won the Business Innovation of the Year Award and was named runner-up for International Business of the Year at the prestigious ...
Compared to chemotherapy alone, Keytruda and Lynparza extended the time to disease progression or death, which MSD – known as Merck & Co in the US and Canada – said was "statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results